Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMAC NASDAQ:HROW NASDAQ:XERS NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$6.74-1.2%$6.46$4.01▼$10.42$362.90M0.97222,825 shs177,071 shsHROWHarrow$38.45-8.2%$39.11$28.54▼$54.85$1.43B0.26600,464 shs888,580 shsXERSXeris Biopharma$8.32-1.1%$7.30$4.87▼$10.08$1.44B0.621.97 million shs1.18 million shsXNCRXencor$19.44-0.5%$13.95$6.92▼$21.26$1.44B0.861.00 million shs632,987 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics0.00%-7.67%+9.59%+6.48%+30.87%HROWHarrow0.00%-17.58%-7.35%-3.15%+4.06%XERSXeris Biopharma0.00%-5.45%+12.43%+37.52%+62.50%XNCRXencor0.00%+11.28%+31.89%+49.77%+103.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$6.74-1.2%$6.46$4.01▼$10.42$362.90M0.97222,825 shs177,071 shsHROWHarrow$38.45-8.2%$39.11$28.54▼$54.85$1.43B0.26600,464 shs888,580 shsXERSXeris Biopharma$8.32-1.1%$7.30$4.87▼$10.08$1.44B0.621.97 million shs1.18 million shsXNCRXencor$19.44-0.5%$13.95$6.92▼$21.26$1.44B0.861.00 million shs632,987 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics0.00%-7.67%+9.59%+6.48%+30.87%HROWHarrow0.00%-17.58%-7.35%-3.15%+4.06%XERSXeris Biopharma0.00%-5.45%+12.43%+37.52%+62.50%XNCRXencor0.00%+11.28%+31.89%+49.77%+103.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMACDiaMedica Therapeutics 2.60Moderate Buy$12.0078.04% UpsideHROWHarrow 2.64Moderate Buy$69.4380.57% UpsideXERSXeris Biopharma 2.57Moderate Buy$10.8029.81% UpsideXNCRXencor 2.50Moderate Buy$24.2524.74% UpsideCurrent Analyst Ratings BreakdownLatest DMAC, XNCR, XERS, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026XERSXeris Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)7/21/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.007/20/2026HROWHarrow Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026DMACDiaMedica Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/7/2026XNCRXencor Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$29.00 ➝ $27.007/6/2026XNCRXencor Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/24/2026XNCRXencor Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.005/12/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.005/11/2026XERSXeris Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/11/2026XNCRXencor JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$13.00 ➝ $14.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.08 per shareN/AHROWHarrow$272.30M5.26$0.86 per share44.49$1.41 per share27.27XERSXeris Biopharma$291.85M4.92$0.10 per share83.06$0.08 per share104.00XNCRXencor$125.58M11.48N/AN/A$8.90 per share2.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMACDiaMedica Therapeutics-$32.77M-$0.71N/AN/AN/AN/A-77.15%-69.23%8/11/2026 (Estimated)HROWHarrow-$5.14M-$0.41N/A17.09N/A-5.57%19.59%2.26%8/10/2026 (Estimated)XERSXeris Biopharma$550K$0.06138.6725.21N/A3.81%735.00%3.24%8/6/2026 (Estimated)XNCRXencor-$91.92M-$2.29N/AN/AN/A-177.10%-28.77%-20.52%8/5/2026 (Estimated)Latest DMAC, XNCR, XERS, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026DMACDiaMedica Therapeutics-$0.19N/AN/AN/A$13.50 millionN/A8/10/2026Q2 2026HROWHarrow-$0.23N/AN/AN/A$70.35 millionN/A8/6/2026Q2 2026XERSXeris Biopharma$0.02N/AN/AN/A$90.13 millionN/A8/5/2026Q2 2026XNCRXencor-$0.84N/AN/AN/A$18.89 millionN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million5/7/2026Q1 2026XERSXeris Biopharma-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 million5/6/2026Q1 2026DMACDiaMedica Therapeutics-$0.17-$0.19-$0.02-$0.19$13.50 millionN/A5/6/2026Q1 2026XNCRXencor-$0.7468-$1.71-$0.9632-$1.71$27.86 million$4.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMACDiaMedica TherapeuticsN/A9.119.11HROWHarrow10.302.482.30XERSXeris Biopharma17.002.121.50XNCRXencorN/A6.576.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMACDiaMedica Therapeutics10.12%HROWHarrow72.76%XERSXeris Biopharma42.75%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipDMACDiaMedica Therapeutics5.00%HROWHarrow12.80%XERSXeris Biopharma4.35%XNCRXencor5.08%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMACDiaMedica Therapeutics2053.88 million51.19 millionOptionableHROWHarrow18037.28 million32.50 millionOptionableXERSXeris Biopharma290172.64 million165.13 millionOptionableXNCRXencor28074.14 million70.38 millionOptionableDMAC, XNCR, XERS, and HROW HeadlinesRecent News About These CompaniesXencor (NASDAQ:XNCR) Stock Price Down 6.7% - Should You Sell?July 22, 2026 | marketbeat.comXencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?July 21, 2026 | marketbeat.comXencor (NASDAQ:XNCR) Sees Unusually-High Trading Volume - Here's WhyJuly 20, 2026 | marketbeat.comXencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?July 20, 2026 | zacks.comXencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim DataJuly 19, 2026 | seekingalpha.comXencor Inc.July 17, 2026 | marketwatch.comXencor advances 17% after revealing ESMO 2026 oral presentation slotJuly 17, 2026 | seekingalpha.comXencor (NASDAQ:XNCR) Stock Price Up 7.9% - What's Next?July 17, 2026 | marketbeat.comXencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaJuly 17, 2026 | businesswire.comXencor: Bullish On Their Increasingly In-House PipelineJuly 14, 2026 | seekingalpha.comXencor (NASDAQ:XNCR) Shares Down 6.6% - Should You Sell?July 13, 2026 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 13, 2026 | marketbeat.comXencor Updates Outlook Amid Ultomiris Royalty DisputeJune 19, 2026 | theglobeandmail.comXencor Shareholders Approve Directors, Incentive Plan AmendmentsJune 18, 2026 | tipranks.comXencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets CautionJune 15, 2026 | uk.finance.yahoo.comIncyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trialMay 30, 2026 | seekingalpha.comXencor IncMay 18, 2026 | money.usnews.comXencor (XNCR) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comXencor, Inc. Common Stock (XNCR)May 13, 2026 | nasdaq.comXencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comThese Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under ThreatMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMAC, XNCR, XERS, and HROW Company DescriptionsDiaMedica Therapeutics NASDAQ:DMAC$6.74 -0.08 (-1.17%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$6.74 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Harrow NASDAQ:HROW$38.45 -3.43 (-8.19%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$39.00 +0.55 (+1.43%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Xeris Biopharma NASDAQ:XERS$8.32 -0.09 (-1.07%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$8.37 +0.05 (+0.60%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Xencor NASDAQ:XNCR$19.44 -0.09 (-0.46%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$19.42 -0.02 (-0.08%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
